ArticlebioRxiv : the preprint server for biology2026
Extended Amygdala CRF Projections to Striatal Striosomes Potentiate Dopamine Suppression During Fentanyl Withdrawal.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Opioid withdrawal is a powerful negative affective state that promotes continued drug use and relapse, and is often associated with hypodopaminergic states. Although corticotropin-releasing factor (CRF) signaling in the extended amygdala has been strongly implicated in stress and negative affect, how withdrawal-recruited CRF systems suppress dopamine release remains poorly understood. Here, we identify an extended amygdala-striosome-dopamine pathway engaged during fentanyl withdrawal. Naloxone-precipitated fentanyl withdrawal selectively recruited CRF neurons in the central amygdala and bed nucleus of the stria terminalis. These CRF neurons provided monosynaptic input to dorsostriatal medium spiny neurons (MSNs). Because striosomal MSNs are positioned to regulate dopamine release, we next found that CRF enhanced glutamatergic synaptic transmission onto striosomal MSNs, with CRF receptor 1 (CRFR1) signaling required for the postsynaptic strengthening of excitatory transmission. In vivo dopamine photometry further revealed that naloxone-precipitated withdrawal amplified striosome-mediated suppression of dopamine release, and this amplification was prevented by CRFR1 antagonism. Together, these findings reveal a mechanism by which withdrawal-recruited CRF signaling potentiates striosomal control of dopamine release. This extended amygdala-striosome-dopamine pathway may contribute to the hypodopaminergic negative affective state that drives opioid withdrawal and relapse vulnerability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.